Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 4

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 4
---
 addition, information concerning the subject matter of the representations and warranties may change after the date of the Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures. Contingent Value Rights Agreement At or prior to the time at which the Arrangement becomes effective, Xeno and Purchaser will authorize and duly adopt, execute and deliver, and will ensure that a rights agent mutually agreeable to Xeno and the Company executes and delivers, a Contingent Value Rights Agreement (the “CVR Agreement”). Each CVR will represent a contractual right to receive contingent cash payments equal to:

| i. | 100% of certain additional receivables that may be received by the Company within ninety (90) days 
 following Closing (net of certain permitted deductions incurred in connection therewith);          |

| ii. | a percentage of the net proceeds received from the Company’s existing partnerships with Bristol-Myers                                                                                                                                                     
 Squibb, Debiopharm and DCx Biotherapeutics, as follows: (i) 90% received from the Closing date until the 2nd anniversary thereof, (ii) 85% received from the 2nd anniversary of the Closing date until the 4th anniversary of the Closing date, (iii) 80% 
 received from the 4th anniversary of the Closing date until the 6th anniversary of the Closing date, and (iv) 75% received from the 6th anniversary of the Closing date until the 10th anniversary of the Closing date;                                   |

| iii. | 100% of the net proceeds received by the 10th anniversary of the Closing date for any license or disposition of                                                     
 the Company’s product candidates and/or intellectual property related to its RP-1664 program, RP-3500 (Camonsertib) program, or any other license or disposition of 
 the Company’s product candidates or research programs if such license or disposition is entered into prior to the Closing date; and                                 |

| iv. | 100% of the net proceeds received by the 10th anniversary of the Closing date for any license or disposition of         
 the Company’s Polq program, RP-3467, to any person with whom negotiations were initiated prior to the Closing date; and |

| v. | 50% of the net proceeds received by the 10th anniversary of the Closing date for any license or disposition of                                                                                  
 the Company’s product candidates and/or intellectual property that occurs within 10 years following the